Tunlametinib

tunlametinib · Shanghai Kechow Pharma, Inc.

Drug timelines are a Plus or Pro feature.

10 regulatory and trial events tracked for Tunlametinib, covering 2024-06-28 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer [Phase 2]